KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $117.6 million.

  • Biogen's Other Operating Expenses fell 5834.22% to $117.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$33.6 million, marking a year-over-year decrease of 11280.49%. This contributed to the annual value of -$33.6 million for FY2025, which is 13792.33% down from last year.
  • Latest data reveals that Biogen reported Other Operating Expenses of $117.6 million as of Q4 2025, which was down 5834.22% from -$34.1 million recorded in Q3 2025.
  • In the past 5 years, Biogen's Other Operating Expenses ranged from a high of $964.1 million in Q4 2021 and a low of -$502.9 million during Q3 2021
  • Its 5-year average for Other Operating Expenses is $51.5 million, with a median of $10.8 million in 2021.
  • In the last 5 years, Biogen's Other Operating Expenses plummeted by 183413.79% in 2021 and then surged by 213442.62% in 2023.
  • Over the past 5 years, Biogen's Other Operating Expenses (Quarter) stood at $964.1 million in 2021, then tumbled by 101.27% to -$12.2 million in 2022, then skyrocketed by 2134.43% to $248.2 million in 2023, then increased by 13.74% to $282.3 million in 2024, then plummeted by 58.34% to $117.6 million in 2025.
  • Its Other Operating Expenses was $117.6 million in Q4 2025, compared to -$34.1 million in Q3 2025 and -$48.7 million in Q2 2025.